Clinical trials
Phase 2 Triple Negative Breast Neoplasms trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
21 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2009 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Terminated | 7 |
| Unknown status | 3 |
| Active, not recruiting | 2 |
| Recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 3 |
| European Institute of Oncology | 2 |
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2 |
| Mario Negri Institute for Pharmacological Research | 2 |
| Merck Sharp & Dohme LLC | 2 |
| AVEO Pharmaceuticals, Inc. | 1 |
| AstraZeneca | 1 |
| Celldex Therapeutics | 1 |
| Consorzio Oncotech | 1 |
| EMD Serono Research & Development Institute, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Triple Negative Breast Neoplasms | 21 |
| Breast Neoplasms | 10 |
| Stomach Neoplasms | 3 |
| Ovarian Neoplasms | 2 |
| Pancreatic Neoplasms | 2 |
| Biliary Tract Neoplasms | 1 |
| Carcinoma, Hepatocellular | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Carcinoma, Renal Cell | 1 |
| Cholangiocarcinoma | 1 |
Trials
Showing 1 to 21 of 21. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.